<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02381808</url>
  </required_header>
  <id_info>
    <org_study_id>CTONG1502</org_study_id>
    <secondary_id>BI1200.250</secondary_id>
    <nct_id>NCT02381808</nct_id>
  </id_info>
  <brief_title>Study on Potential Biomarkers Associated With Clinical Phenotype of EGFR-TKIs in No-small Cell Lung Cancer in China</brief_title>
  <official_title>Study on Potential Biomarkers Associated With Clinical Phenotype of EGFR-TKIs in No-small Cell Lung Cancer in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong Association of Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Guangdong Association of Clinical Trials</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To understand 295 gene mutation mutation status (include EGFR, HER2, KRAS, BRAF, PIK3CA,ect)&#xD;
      by deep sequencing in Chinese patients with pulmonary adenocarcinoma and their relationships&#xD;
      with the patients' clinical features (including sex, age, smoking history and adenocarcinoma&#xD;
      subtype), specify the predictive significance of the genes mutations for new targeted&#xD;
      therapies in NSCLC patients, and better understand the molecular mechanism drug resistance to&#xD;
      EGFR-TKIs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is prospective to identify biomarkers to resistant to afatinibï¼Œgefitinib and&#xD;
      erlotinib in non-small cell lung cancer patients. Mutations of whole exon of 295 gene are&#xD;
      analysed by deep sequencing in Chinese patients with non-small cell lung cancer and their&#xD;
      relationships with the patients' clinical features (including sex, age, smoking history and&#xD;
      adenocarcinoma subtype), specify the predictive significance of the genes mutations for new&#xD;
      targeted therapies in NSCLC patients, and better understand the molecular mechanism drug&#xD;
      resistance to EGFR-TKIs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 24, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Potential predictive biomarker to resistant to afatinib</measure>
    <time_frame>baseline</time_frame>
    <description>Mutations of whole exon of 295 gene are analysed by deep sequencing in Chinese patients with NSCLC and their relationships with the patients' clinical features , specify the predictive significance of the genes mutations for new targeted therapies in NSCLC patients, and better understand the molecular mechanism drug resistance to EGFR-TKIs</description>
  </primary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Frozen tissue or tissue block&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        NSCLC (SageI-IV)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age&gt;18 years,both male and female&#xD;
&#xD;
          -  Histologically confirmed patients with pulmonary adenocarcinoma (Stage I-IV)&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
          -  Patients with enough paraffin tissue specimens or fresh tissue for detection&#xD;
&#xD;
          -  Quality of the DNA extracted from the tissue samples ensures that the DNA can be used&#xD;
             in DNA sequencing&#xD;
&#xD;
          -  Subjects who provide detailed clinical and follow-up information&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with other tumors&#xD;
&#xD;
          -  Patients suffering from other serious diseases like infectious diseases (viral&#xD;
             hepatitis, HIV,etc)&#xD;
&#xD;
          -  Pregnant women shall be excluded&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>China China</last_name>
    <role>Study Chair</role>
    <affiliation>Guang general hospital,Guangzhou, Guangdong, China, 510080</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guangdong General Hospital &amp; Guangdong Academy of Medical Sciences</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>March 5, 2015</study_first_submitted>
  <study_first_submitted_qc>March 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2015</study_first_posted>
  <last_update_submitted>June 5, 2017</last_update_submitted>
  <last_update_submitted_qc>June 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

